相关实验视频

Updated: May 5, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

29.8K

早期与晚年发病阿尔茨海默氏症的不同Tau PET动态

Konstantinos Chiotis, Ganna Blazhenets, David N Soleimani-Meigooni

    medRxiv : the preprint server for health sciences
    |February 6, 2026
    PubMed
    概括

    早期发病的阿尔茨海默病 (EOAD) 与晚期发病的AD (LOAD) 相比,涉及更具攻击性的tau传播. 在EOAD中这种激进的病导致更快的临床衰退,这表明可能需要不同的治疗策略.

    更多相关视频

    Assessment of Social Transmission of Food Preferences Behaviors04:56

    Assessment of Social Transmission of Food Preferences Behaviors

    Published on: January 25, 2018

    7.8K
    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-145105:17

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

    Published on: April 18, 2025

    1.1K

    相关概念视频

    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
    1.7K
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    1.3K
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
    29
    Alzheimer Disease ll: Pathophysiology01:23

    Alzheimer Disease ll: Pathophysiology

    Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
    42
    Dementia l: Introduction01:22

    Dementia l: Introduction

    Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
    35